Compare HUT & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | TECH |
|---|---|---|
| Founded | 2011 | 1976 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 11.3B |
| IPO Year | 2023 | 1995 |
| Metric | HUT | TECH |
|---|---|---|
| Price | $87.48 | $72.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $65.20 | ★ $71.82 |
| AVG Volume (30 Days) | ★ 4.9M | 2.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.62% |
| EPS Growth | N/A | ★ 152.17 |
| EPS | N/A | ★ 1.16 |
| Revenue | $235,118,000.00 | ★ $1,215,039,000.00 |
| Revenue This Year | $161.69 | $2.49 |
| Revenue Next Year | N/A | $6.40 |
| P/E Ratio | ★ N/A | $62.40 |
| Revenue Growth | ★ 44.79 | N/A |
| 52 Week Low | $24.20 | $43.20 |
| 52 Week High | $140.80 | $72.62 |
| Indicator | HUT | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 67.84 |
| Support Level | $87.39 | $71.89 |
| Resistance Level | $112.33 | $72.62 |
| Average True Range (ATR) | 6.68 | 0.22 |
| MACD | 0.62 | -0.26 |
| Stochastic Oscillator | 65.76 | 61.29 |
Hut 8 Corp is an energy infrastructure platform that integrates power, digital infrastructure, and compute at scale to fuel next-generation, energy-intensive use cases. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.